Review Article

Use of Chlorogenic Acid against Diabetes Mellitus and Its Complications

Yongwang Yan,1,2 Xu Zhou,3 Kangxiao Guo,2 Feng Zhou,2 and Hongqi Yang1

1College of Bioscience and Biotechnology, Hunan Agricultural University, Changsha, China
2Pharmaceutical College, Changsha Health Vocational College, Changsha, China
3Department of Gastroenterology, Changsha Hospital of Traditional Chinese Medicine, Changsha, China

Correspondence should be addressed to Hongqi Yang; csyhq@sina.com

Received 25 March 2020; Revised 27 April 2020; Accepted 4 May 2020; Published 28 May 2020

Guest Editor: Kai Wang

Copyright © 2020 Yongwang Yan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Chlorogenic acid (CA) is a phenolic compound commonly found in human plant-based diets. CA is the main component of many traditional Chinese medicine preparations, and in recent years, it has been found to have hypoglycemic, hypolipidemic, anti-inflammatory, antioxidant, and other pharmacological properties. Specifically, CA relieves the effects of, and prevents, diabetes mellitus (DM). In addition, CA is also beneficial against complications arising from DM, such as diabetic nephropathy (DN), diabetic retinopathy (DR), and diabetic peripheral neuropathy (DPN). Herein, we review the use of CA in the prevention and treatment of DM and its complications, providing a background for further research and medical uses.

1. Introduction

Chlorogenic acid (CA), also called 5-caffeoylquinic acid (5-CQA) [1], belongs to the hydroxycinnamic acid family, and is formed by caffeic acid and quinic acid [2, 3]. CA is produced in plants in the shikimic acid pathway during aerobic respiration. This compound is an ingredient, not only in foods, but also in traditional Chinese medicine preparations [4, 5]. In the latter, it has been found to exert hypoglycemic [6, 7], hypolipidemic [8], antibacterial [9], antioxidant [10], and anti-inflammatory [11] effects. In this context, the hypoglycemic and hypolipidemic effects of CA have attracted attention, specifically in their possible application in the prevention and treatment of diabetes mellitus (DM) [12–14]. DM is a metabolic disease caused by abnormal insulin function and characterized by hyperglycemia. Its main subtypes are (1) type 1, with absolute insulin deficiency, and (2) type 2 DM, or noninsulin-dependent DM, with relative insulin deficiency and resistance.

According to estimates of the World Health Organization, DM affects 366 million patients worldwide, a number expected to grow to 500 million by 2030 [15]. DM is a high-risk factor for stroke, heart disease, and kidney disease, thus, seriously affecting the quality of life and severely restricting social and economic development [16]. Despite many studies reported the use of CA against DM and its complications, these studies have not been systematic, and information is scattered in the literature. The present review aims at organizing this information for further research work and medical use.

2. Use of CA to Prevent and Treat DM

2.1. Effect of CA on Glucose Metabolism. Persistent hyperglycemia is the overriding feature of DM. At the time of the onset of DM, islet β cells continuously and excessively secrete insulin to reduce blood glucose, which eventually causes islet β cell injury and aggravates hyperglycemia. Under persistent hyperglycemia, glucose toxicity causes DM chronic complications [16]. CA has been shown to reduce fasting blood glucose; for example, when 15 patients with impaired glucose tolerance were exposed to 400 mg CA, administered three times a day for 12 weeks, in a randomized, double-blind, placebo-controlled clinical trial [12]. In other clinical trials, CA-containing green coffee bean extract was used to reduce fasting blood glucose in 21 patients with metabolic disease,
when the extract was administered in 400 mg capsules given twice a day for a total of 8 weeks [14]. Further, blood glucose in mice on a high-fat diet treated with green coffee bean extract, which is majorly composed of CA, was significantly lower than in a control group, when the extract reached 100 mg/kg body weight, after six weeks [17]. In another study, rats with type 2 DM were treated with CA-containing mulberry leaf extract, rutin, or isoquercitrin for 11 days. While mulberry leaf extract, CA, and rutin markedly reduced blood glucose in the treated rats, isoquercitrin had no obvious hypoglycemic effect, suggesting that over 50% of the hypoglycemic effect observed in mulberry leaf extract could be attributed to CA and rutin [18]. Also, lower fasting blood glucose and a raised muscle glycogen were found in laboratory db/db mice when administered CA by gavage at a dose of 80 mg/kg/day for 12 weeks [19]. During a study of the effect of CA on postprandial blood glucose content, Tunnicliffe et al. [20] found that blood glucose in rats treated with CA for 60 min after a meal was markedly lower than in rats treated with placebo. Finally, lower than normal blood glucose was reported when streptozotocin-nicotinamide-induced DM rats were treated with CA at a dose of 5 mg/kg/day for 45 days, with levels in treated and control rats of 105.2 and 282.28 mg/dL, respectively [21].

2.2. Effect of CA on Lipid Contents. Dysfunctional lipid metabolism is a well-known high-risk factor in DM [16], and several reports have highlighted the effect of CA in improving lipid metabolism. In Wistar rats exposed to a high-glucose and high-fat diet, CA improved lipid metabolism, reduced weight gain, liver weight, mesenteric and epididymal fat weight, contents of liver cholesterol, triglyceride, free fatty acids, and plasma free fatty acids [13]. Similar observations were reported in other animal experiments regarding weight gain, liver weight, and plasma free fatty acids [17], and in mice exposed to a high-fat diet, green coffee bean extract which is majorly composed of CA reduced plasma triglycerides, low-density lipoproteins, and high-density lipoproteins. Ong et al. [22] reported that db/db mice treated with CA at a dose of 250 mg/kg/day for 14 days showed significantly reduced levels of total cholesterol, triglycerides, and free fatty acids in plasma, relative to a control group. Moreover, liver histomorphology showed that CA inhibited the formation of fat particles in the hepatocytes of treated mice.

In SD rats exposed to a high-glucose and high-fat diet, CA dramatically reduced total cholesterol, low-density lipoprotein, high-density lipoprotein in plasma, and liver lipid content [23], but had no effect on triglycerides. This is in contrast with another report [19] that claimed just the opposite; an effect of CA on triglycerides, but no reduction of free fatty acids and total cholesterol in blood, liver, or muscle.

In a study that assessed the effect of CA and tetrahydrocurcumin on blood lipids in DM rats, CA significantly reduced contents of cholesterol, triglycerides, free fatty acids, high-density lipoproteins, low-density lipoproteins, very low-density lipoproteins in plasma, and lipids in liver and kidney [21]. Finally, in golden hamsters fed a high-fat diet, CA inhibited weight gain by reducing the content of visceral fat, plasma triglycerides, total cholesterol, free fatty acids, high-density lipoprotein, and low-density lipoprotein, as well as triglyceride and total cholesterol in the liver and free fatty acid in muscles [24].

2.3. Effects of CA on Insulin Secretion and Resistance. CA has been reported to relieve insulin resistance which is the direct cause of DM [25, 26]. In a clinical test [12], a decline in fasting blood glucose and insulin secretion of patients treated with CA for 12 weeks, suggested that CA can ameliorate insulin resistance and enhance insulin sensitivity. However, in another clinical experiment, CA did not increase the secretion of glucagon-like peptide-1 and glucose-dependent insulin-stimulating hormone [27]. Experiments performed in β cells pretreated with CA have shown that the secretion of insulin was increased after culture in media with 4 mM or 10 mM of glucose [28]. In another experiment with the INS-1E insulin-secreting cell line and rat islets of Langerhans, stimulation of insulin secretion was observed after treatment with 50 μg/mL CA; the effect was close to that caused by 5 mM of glucose, whereas in 8.3 mM of glucose, CA significantly increased the secretion of insulin [29]. Rats exposed to a high-fat diet and administered 50 mg/kg CA for 20 weeks showed an increase in insulin secretion and an improvement in insulin resistance [30]. Also, CA treatment of both high-fat diet-induced obese mice and spontaneously obese mice reduced hyperinsulinemia and enhanced insulin sensitivity, suggesting that CA can improve obesity-related insulin resistance [31]. In mice exposed to high-fat milk, CA elevated insulin sensitivity and reduced insulin resistance [32]. Finally, when obese mice were exposed to a high-fat diet, the administration of CA-containing green coffee bean extract reduced the insulin resistance in a dose-dependent manner [33]. However, other clinical experiments have shown that the observed coffee-induced reduction of liver insulin resistance caused by short-term fructose overdose cannot be attributed to CA or caffeine, but to other unidentified active compounds [34].

2.4. Effect of CA on the Activity of Enzymes Involved in Glucose and Lipid Metabolism. The activity of glucose and lipid metabolism-associated enzymes and their regulation by natural products has become a research focus in the prevention and treatment of DM [35]. In vitro, CA modulates the activity of enzymes involved in glucose metabolism. Indeed, 100 μg/mL CA competitively inhibited α-amylase, reducing its activity by 75%, similar to the inhibitory effect of acarbose [36], which is consistent with the results by Oboh et al. [37]. CA has also been shown to inhibit α-glucosidase activity, but this effect was far weaker than that of acarbose [38]. Other in vitro studies have shown that CA competitively inhibits glucose-6-phosphatase in the liver and reduces the hydrolysis of hepatic glycogen, thus contributing to the prevention and treatment of DM [39].

In a previous study, a 4-caffeoyl group was shown to be responsible for the observed inhibition by CA [40]. CA inhibited both isozymes of porcine pancreatic α-amylase (PPA), PPA-I, and PPA-II, suggesting that α-amylase inhibitors could be used to prevent and treat DM. CA can also modulate
the activity of enzymes involved in lipid metabolism. Wenna et al. [41] showed that either a CA-containing extract of *Eucommia ulmoides* or pure CA reduced intestinal absorption and further conversion of lipid and cholesterol and also reduced liver cholesterol synthesis. However, in that study, the inhibition of pancreatic lipase activity was stronger for the *Eucommia ulmoides* extract than for the same concentration of control CA, suggesting that the extract may also contain other effective synergistic components. Lastly, in obese mice exposed to a high-fat diet, CA regulated lipid metabolism by inhibiting the activity of fatty acid synthase, HMG-CoA reductase, and cholesterol acyltransferase [42].

2.5. Effects of CA on DM Signal Transduction Pathways. Insulin mediates glucose metabolism in the body and exerts its biological activity after interaction with receptors. The signal is then transferred to the cell interior mainly via a tyrosine kinase pathway. Insulin signal transduction involves the insulin receptor substrate (IRS), phosphatidylinositol-3-kinase (PI3K) and serine/threonine kinase (Akt), and the glucose transporter (GLUT), which are the foci of current research on the molecular mechanism of insulin resistance [43].

CA is the main phenolic acid in *Sonchus oleraceus*, which improved insulin sensitivity in HepG2 cells [44]. It also reduced the decrease in IRS-1 expression caused by high insulin concentration, prevented inactivation of the PI3K/Akt pathway, and also prevented GLUT4 level reduction observed after high glucose exposure. These results are consistent with those of Liang et al. [32], where CA-treated mice previously exposed to high-fat milk showed an increase in GLUT4 mRNA levels in skeletal muscle. However, other components in the phenolic acid extract from *Sonchus oleraceus* other than CA may be responsible for this effect. Similarly, whether the effect on the tyrosine kinase pathway is exerted by CA or by other components remains unknown.

In intestinal segments of rats exposed to a high-fat diet, Peng et al. [45] showed the suppression of GLUT2 downregulation after CA administration. Moreover, animal experiments showed that this downregulation may have been mediated by the activation of adenosine 5′-monophosphate-activated protein kinase (AMPK) facilitated by CA [46]. Indeed, these authors showed that CA promoted phosphorylation of AMPK and Akt to increase the transport of GLUT4 to plasma membranes, thus facilitating the transport of glucose. In fact, GLUT4 transportation could not be observed after the knockout of AMPKα1/2 or AMPK inhibition. CA was also shown to promote the expression and translocation of GLUT4, eventually inhibiting liver glucose production, but this inhibition disappeared after AMPK inhibition or knockout [23]. Nevertheless, caffeic acid, a metabolite of CA, rather than CA itself, may be ultimately responsible for the activation of AMPK in skeletal muscle to facilitate glucose transport [47].

2.6. Effects of CA on Oxidative Stress and Inflammatory Response. Oxidative stress and inflammatory response are key factors in the occurrence and development of type 2 DM [48–50]. These factors result in islet β cell injury [51, 52], accelerate insulin resistance [53, 54], and increase the development of DM-related complications [55, 56]. Therefore, the prevention and treatment of DM should benefit from alleviating oxidative stress and inflammatory response.

In DM model rats, the administration of CA reduced the content of lipid hydrogen peroxide and increased the content in nonenzymatic antioxidants in the blood such as glutathione (GSH), vitamin C, vitamin E, and ceruloplasmin [57], suggesting that CA protects against DM exposed to streptozotocin-nicotinamide-induced oxidative stress. In liver and kidney, CA reduced the levels of thioarbituric acid reactive substances and hydroperoxide and enhanced the activity of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), and glutathione S-transferase (GST) [58]. In liver and white adipose tissues, CA inhibited protein and mRNA expression of F4/80 and CD68 and relieved inflammatory response [31]. In addition, CA had a protective effect on insulin secreting-IE (INS-1E) cells exposed to streptozotocin (STZ) [28]. In that study, CA promoted insulin secretion in INS-1E cells and increased GSH content and GSH-Px activity. Also, it reduced the production of reactive oxygen species (ROS) and the morphological changes of cells caused by STZ, thus protecting β cells.

3. Use of CA to Prevent and Treat DM-Related Complications

3.1. Effects of CA on Diabetic Nephropathy (DN). DN is one of the most common microvascular complications of DM and also one of the main causes of death in DM patients [59]. There have been some attempts to use CA in the prevention and treatment of DN. In experimental DM rats, CA decreased kidney malondialdehyde (MDA) levels, increased SOD and GSH-Px activity, and reduced the expression of factors (IL-6, TNF-α, and IL-1β) related to oxidative stress and inflammatory response in the kidney [60]. In that study, pathological examination found that CA reduced glomerular hypertrophy and mesangial matrix expansion. Another animal experiment was consistent with these results, showing that CA enhanced SOD, GSH-Px, and CAT activity in the liver, reduced the MDA levels, downregulated the expression of cyclooxygenase 2 (COX-2) protein, and reduced the proliferation and mesangial expansion of mesangial cells [61]. Thus, the above results suggest that CA may prevent and treat DN by relieving oxidative stress and inflammatory response in the kidney.

3.2. Effects of CA on Diabetic Retinopathy (DR). DR is a microvascular complication of DM that is the main cause of vision impairment in the middle-aged and elderly people worldwide [62]. Thus, the role of CA in the prevention and treatment of DR has been the subject of intense research. Treatment of DM mice with honeysuckle extract, shown by high-efficiency liquid chromatography to mainly contain CA, suppressed STZ-induced retinal vascular proliferation and reduced content of vascular endothelial growth factor
(VEGFs) in serum [63]. Also, in cellular and animal experiments, CA counteracts the effect of hypoxia-inducible factor 1-α and decreases VEGF expression during DR, thus improving retinal neovascularization. These results are consistent with retinal immunofluorescence staining of clusters of differentiation and histopathological observations [64]. In addition, in DM rats, CA improved the reduction in occludin, a tight junction protein and a component of the blood-retinal barrier, and inhibited the expression of VEGFs [65]. Overall, the above results show that CA can mitigate the effect of DR in the context of retinal vascular permeability.

3.3. Effects of CA on Diabetic Peripheral Neuropathy (DPN). One of the most common chronic complications of DM is diabetic systemic disease, mainly manifested as peripheral neuropathy [66]. Thus, studies have been directed towards the effect of CA on diabetic neuropathy. In DM mice, CA improved the auditory function of the external auditory canal, alleviated the dysfunction of the central auditory pathway, contributed to the recovery of cochlear outer hair cell injury, prevented neurona, and protected ear hair cells [67]. These effects are consistent with an ameliorating effect of CA on the auditory function. Also, using a mechanical claw pressure test, CA was effective to relief DM-induced neuropathic pain, possibly through reducing blood glucose level and alleviating oxidative stress [68].

4. Summary and Outlook

CA is a natural product obtainable from a variety of sources that has a wide pharmacological range. Compared with the existing hypoglycemic drugs, it has low toxicity or side effects. Because of its multisystem and multitarget pharmacological effects, CA may become a useful clinical drug in the treatment of the complex pathogenesis typical of DM and also its related complications. However, the present review shows that there are still many limitations in the application of CA for this purpose. First, despite the use of CA in the prevention and treatment of DM in different conditions, the mechanism of action and specific targets remain unclear. Second, the dosage of CA applied in DM needs to be confirmed by further evidences. Third, past efforts have only focused on DN, DR, and DPN, but these studies involve no diabetic cerebrovascular diseases and diabetic heart diseases. Fourth, there is a potential for the combined application of CA with Western hypoglycemic drugs or with other traditional Chinese medicines. These may bring reduced toxicity and enhanced efficacy to attack the most salient effect of DM, which is blood glucose. Finally, the development of CA as a new drug for the prevention and treatment of DM requires improvement in stability, solubility, and oral absolute bioavailability.

Conflicts of Interest

The authors declared that there are no conflicts of interest.

Acknowledgments

This work was supported by the Scientific Research Fund of the Hunan Provincial Education Department (No. 17C0123) and the Scientific Research Fund of the Hunan Provincial health and planning Business Committee (No. C2017010). The authors would like to express their gratitude to EditSprings (https://www editsprings com/) for the expert linguistic services provided.

References

[1] L. G. Naso, M. Valcarcel, M. Roura-Ferrer et al., “Promising antioxidant and anticancer (human breast cancer) oxidadum(IV) complex of chlorogenic acid. Synthesis, characterization and spectroscopic examination on the transport mechanism with bovine serum albumin,” Journal of Inorganic Biochemistry, vol. 135, pp. 86–99, 2014.
[2] D. Kremr, T. Bajer, P. Bajerová, S. Surmová, and K. Ventura, “Unremitting problems with chlorogenic acid nomenclature: a review,” Quimica Nova, vol. 39, no. 4, pp. 530–533, 2016.
[3] L.-N. Wang, W. Wang, M. Hattori, M. Daneshtalab, and C.-M. Ma, “Synthesis, anti-HCV, antioxidant and reduction of intracellular reactive oxygen species generation of a chlorogenic acid analogue with an amide bond replacing the ester bond,” Molecules, vol. 21, no. 6, p. 737, 2016.
[4] K. Ferrare, L. P. R. Bidel, A. Awwad et al., “Increase in insulin sensitivity by the association of chicoric acid and chlorogenic acid contained in a natural chicoric acid extract (NCRAE) of chicory (Cichorium intybus L.) for an antidabetic effect,” Journal of Ethnopharmacology, vol. 215, pp. 241–248, 2018.
[5] A. Venditti, A. Bianco, C. Frezza et al., “Essential oil composition, polar compounds, glandular trichomes and biological activity of Hyssopus officinalis subsp. aristatus (Goddr.) Nyman from Central Italy,” Industrial Crops and Products, vol. 77, pp. 353–363, 2015.
[6] S. Jin, C. Chang, L. Zhang, Y. Liu, X. Huang, and Z. Chen, “Chlorogenic acid improves late diabetes through adiponectin receptor signaling pathways in db/db mice,” PLoS One, vol. 10, no. 4, article e120842, 2015.
[7] K. Huang, X. Liang, Y. Zhong, Y. Ye, and Z. Wang, “5-Caffeoylquinic acid decreases diet-induced obesity in rats by modulating PPARα and LXRα transcription,” Journal of the Science of Food and Agriculture, vol. 95, no. 9, pp. 1903–1910, 2015.
[8] S. Hao, Y. Xiao, Y. Lin et al., “Chlorogenic acid-enriched extract from Eucommia ulmoides leaves inhibits hepatic lipid accumulation through regulation of cholesterol metabolism in HepG2 cells,” Pharmaceutical Biology, vol. 54, no. 2, p. 251, 2015.
[9] E. Bajko, M. Kalinowska, P. Borowski, L. Siergiejczyk, and W. Lewandowski, “5-O-Caffeoylquinic acid: a spectroscopic study and biological screening for antimicrobial activity,” LWT–Food Science and Technology, vol. 65, pp. 471–479, 2016.
[10] K.-L. Tsai, C.-H. Hung, S.-H. Chan et al., “Chlorogenic acid protects against oxLDL-induced oxidative damage and mitochondrial dysfunction by modulating SIRT1 in endothelial cells,” Molecular Nutrition & Food Research, vol. 62, no. 11, article 1700928, 2018.
[11] K. C. D. Santos, B. G. Bueno, L. F. Pereira et al., “Yacon (Smal- lanthus sonchifolius) leaf extract attenuates hyperglycemia and skeletal muscle oxidative stress and inflammation in diabetic
ratax, “Evidence-based Complementary and Alternative Medicine,” vol. 2017, Article ID 6418048, 9 pages, 2017.

12. L. Y. Zhúgí, M. C. Abeeves-de Abeves-de la Mora, M. González-Ortiz, J. L. Ramos-Núñez, and E. Martinez-Abundis, “Effect of chlorogenic acid administration on glycemic control, insulin secretion, and insulin sensitivity in patients with impaired glucose tolerance,” Journal of Medicinal Food, vol. 21, no. 5, pp. 469–473, 2018.

13. H. V. Sucpeer, K. Venkatakrisnya, D. Patel, and K. Shyamprasad, “Biology mechanism of chlorogenic acid complex mediated plasma free fatty acid metabolism in rat liver,” BMC Complementary and Alternative Medicine, vol. 16, no. 1, p. 274, 2016.

14. H. Roshan, O. Nikpayam, M. Sedaghat, and G. Sohrab, “Effects of green coffee extract supplementation on anthropometric indices, glycaemic control, blood pressure, lipid profile, insulin resistance and appetite in patients with the metabolic syndrome: a randomised clinical trial,” British Journal of Nutrition, vol. 119, no. 3, pp. 250–258, 2018.

15. American Diabetes Association, “2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018,” Diabetes Care, vol. 41, Supplement 1, pp. S13–S27, 2018.

16. Organization W H, Global report on diabetes, World Health Organization, 2016.

17. B.-K. Choi, S.-B. Park, D.-R. Lee et al., “Green coffee bean extract improves obesity by decreasing body fat in high-fat diet-induced obese mice,” Asian Pacific Journal of Tropical Medicine, vol. 9, no. 7, pp. 635–643, 2016.

18. A. Hunyadi, A. Martins, T. J. Hsieh, A. Seres, and I. Zupkó, “Chlorogenic acid and rutin play a major role in the in vivo anti-diabetic activity of Morus alba leaf extract on type II diabetic rats,” PLoS One, vol. 7, no. 11, article e50619, 2012.

19. L. T. Zhang, C. Q. Chang, Y. Liu, and Z. M. Chen, “Effect of chlorogenic acid on disordered glucose and lipid metabolism in db/db mice and its mechanism,” Acta Academiae Medicinae Sinicae, vol. 33, no. 3, pp. 281–286, 2011.

20. J. M. Tunniclliffe, L. K. Eller, R. A. Reimer, D. S. Hittel, and J. Shearer, “Chlorogenic acid differentially affects postprandial glucose and glucose-dependent insulinotropic polypeptide response in rats,” Applied Physiology, Nutrition, and Metabolism, vol. 36, no. 5, pp. 650–659, 2011.

21. K. Karthikesan, L. Pari, and V. Menon, “Combined treatment of tetrahydrocurcumin and chlorogenic acid exerts potential antihyperglycemic effect on streptozotocin-nicotinamide-induced diabetic rats,” General Physiology and Biophysics, vol. 29, no. 1, pp. 23–30, 2010.

22. K. W. Ong, A. Hsu, and B. K. H. Tan, “Anti-diabetic and anti-lipidemic effects of chlorogenic acid are mediated by ampk activation,” Biochemical Pharmacology, vol. 85, no. 9, pp. 1341–1351, 2013.

23. C.-W. Wan, C. N.-Y. Wong, W.-K. Pin et al., “Chlorogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by up-regulating the gene expression of PPAR-α in hypercholesterolemic rats induced with a high-cholesterol diet,” Phytotherapy Research, vol. 27, no. 4, pp. 545–551, 2013.

24. S.-Y. Li, C.-Q. Chang, F.-Y. Ma, and C.-L. Yu, “Modulating effects of chlorogenic acid on lipids and glucose metabolism and expression of hepatic peroxisome proliferator-activated receptor-α in golden hamsters fed on high fat diet,” Biomedical and Environmental Sciences, vol. 22, no. 2, pp. 122–129, 2009.

25. L. Bennett, P. W. Franks, B. Zöller, and L. Groop, “Family history of diabetes and its relationship with insulin secretion and insulin sensitivity in Iraqi immigrants and native swedes: a population-based cohort study,” Acta Diabetologica, vol. 55, no. 3, pp. 233–242, 2018.

26. A. Abderrahmani, L. Yengo, R. Caiazzo et al., “Increased hepatic PDGF-AA signaling mediates liver insulin resistance in obesity associated type 2 diabetes,” Diabetes, vol. 67, no. 7, pp. 1310–1321, 2018.

27. M. R. Olthof, A. E. van Dijk, C. F. Deacon, R. J. Heine, and R. M. van Dam, “Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on incretin hormones,” Nutrition & Metabolism, vol. 8, no. 1, p. 10, 2011.

28. B. Fernandez-Gomez, S. Ramos, L. Goya, M. D. Mesa, M. D. del Castillo, and M. Á. Martin, “Coffee silverskin extract improves glucose-stimulated insulin secretion and protects against streptozotocin-induced damage in pancreatic INS-1E beta cells,” Food Research International, vol. 89, pp. 1015–1022, 2016.

29. D. Tousch, A.-D. Lajoex, E. Hosy et al., “Chicoric acid, a new compound able to enhance insulin release and glucose uptake,” Biochemical and Biophysical Research Communications, vol. 377, no. 1, pp. 131–135, 2008.

30. H. Yan, Y.-Q. Gao, Y. Zhang, H. Wang, G.-S. Liu, and J.-Y. Lei, “Chlorogenic acid alleviates autophagy and insulin resistance by suppressing INK pathway in a rat model of nonalcoholic fatty liver disease,” Journal of Biosciences, vol. 43, no. 2, pp. 287–294, 2018.

31. Y. Ma, M. Gao, and D. Liu, “Chlorogenic acid improves high fat diet-induced hepatic steatosis and insulin resistance in mice,” Pharmaceutical Research, vol. 32, no. 4, pp. 1200–1209, 2015.

32. X. C. Liang, W. Meng, Y. L. Zhong, L. Huang, W. Y. He, and Z. Wang, “Effects of chlorogenic acid on mouse insulin resistance development induced by high fat emulsion,” Chinese Pharmacological Bulletin, vol. 29, no. 5, pp. 654–658, 2013.

33. J. S. Song, S. Choi, and T. Park, “Decaffeinated green coffee bean extract attenuates diet-induced obesity and insulin resistance in mice,” Evidence-based Complementary and Alternative Medicine, vol. 2014, Article ID 718379, 14 pages, 2014.

34. V. Lecoulitre, G. Carrel, L. Egli et al., “Coffee consumption attenuates short-term fructose-induced liver insulin resistance in healthy men,” The American Journal of Clinical Nutrition, vol. 99, no. 2, pp. 268–275, 2014.

35. D. Liu, H. Gao, W. Tang, and S. Nie, “Plant non-starch polysaccharides that inhibit key enzymes linked to type 2 diabetes mellitus,” Annals of the New York Academy of Sciences, vol. 1401, no. 1, pp. 28–36, 2017.

36. V. C. Pérez-Nájera, J. A. Gutiérrez-Uribe, M. Antunes-Ricardo et al., “Smailax aristolochiifolia root extract and its compounds chlorogenic acid and astilbin inhibit the activity of a-amylase and a-glucosidase enzymes,” Evidence-based Complementary and Alternative Medicine, vol. 2018, 12 pages, 2018.

37. G. Obhob, O. M. Aguñoye, S. A. Adeyegha, A. J. Akinwemi, and A. O. Adegueli, “Caffeic and chlorogenic acids inhibit key enzymes linked to type 2 diabetes (in vitro): a comparative study,” Journal of Basic and Clinical Physiology and Pharmacology, vol. 26, no. 2, pp. 165–170, 2015.

38. H. X. Liu, M. L. Li, B. Tan, H. H. Chen, and Y. Lu, “Inhibitory effects of chlorogenic acid and isochlorogenic acid from purple sweet potato leaves on a-glucosidase,” Modern Food Science & Technology, vol. 30, no. 3, pp. 103–107, 2014.
[39] C. Henry-Vitrac, A. Ibarra, M. Roller, J. M. Mériton, and X. Vitrac, “Contribution of chlorogenic acids to the inhibition of human hepatic glucose-6-phosphatase activity in vitro by Svetol, a standardized decaffeinated green coffee extract,” *Journal of Agricultural and Food Chemistry*, vol. 58, no. 7, pp. 4141–4144, 2010.

[40] Y. Narita and K. Inouye, “Kinetic analysis and mechanism on the inhibition of chlorogenic acid and its components against porcine pancreas α-amylase isozymes I and II,” *Journal of Agricultural and Food Chemistry*, vol. 57, no. 19, pp. 9218–9225, 2009.

[41] W. N. Li, Y. D. Han, Y. H. Liu, Y. Chen, and Y. Xiao, “Effects of chlorogenic acid extract from leaves of Eucommia ulmoides on key enzyme activities in lipid metabolism,” *Traditional Chinese Drug Research & Clinical Pharmacology*, vol. 23, 2012.

[42] A.-S. Cho, S.-M. Jeon, M.-J. Kim et al., “Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice,” *Food and Chemical Toxicology*, vol. 48, no. 3, pp. 937–943, 2010.

[43] A. Balerczyk, S. Chriett, and L. Pirola, “Insulin action, insulin resistance, and their link to histone acetylation,” in *Handbook of Nutrition, Diet, and Epigenetics*, V. Patel and V. Preedy, Eds., pp. 809–830, Springer, Cham, 2019.

[44] L. Chen, H. Teng, and H. Cao, “Chlorogenic acid and caffeic acid from Sonchus oleraceus Linn synergistically attenuate insulin resistance and modulate glucose uptake in HepG2 cells,” *Food and Chemical Toxicology*, vol. 127, pp. 182–187, 2019.

[45] B. J. Peng, Q. Zhu, Y. L. Zhong, S. H. Xu, and Z. Wang, “Chlorogenic acid maintains glucose homeostasis through modulating the expression of SGLT-1, GLUT-2, and PLG in different intestinal segments of Sprague-Dawley rats fed a high-fat diet,” *Biomedical and Environmental Sciences*, vol. 28, no. 12, pp. 894–903, 2015.

[46] K. W. Ong, A. Hsu, and B. K. Tan, “Chlorogenic acid stimulates glucose transport in skeletal muscle via AMPK activation: a contributor to the beneficial effects of coffee on diabetes,” *PLoS One*, vol. 7, no. 3, article e32718, 2012.

[47] S. Tsuda, T. Egawa, X. Ma, R. Oshima, E. Kurogi, and T. Hayashi, “Coffee polyphenol caffeic acid but not chlorogenic acid increases 5’AMP-activated protein kinase and insulin-independent glucose transport in rat skeletal muscle,” *The Journal of Nutritional Biochemistry*, vol. 23, no. 11, pp. 1403–1409, 2012.

[48] E. J. Henriksen, “Chapter 1 - Role of Oxidative Stress in the Pathogenesis of Insulin Resistance and Type 2 Diabetes,” in *Bioactive Food as Dietary Interventions for Diabetes (Second Edition)*, pp. 3–17, Academic Press, 2019.

[49] L. Fuentes, T. Rösser, and M. Ricote, “Inflammatory mediators and insulin resistance in obesity: role of nuclear receptor signaling in macrophages,” *Mediators of Inflammation*, vol. 2010, 10 pages, 2010.

[50] M. S. Burhans, D. K. Hagman, J. N. Kuzma, K. A. Schmidt, and M. Kratz, “Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus,” *Comprehensive Physiology*, vol. 9, no. 1, pp. 1–58, 2018.

[51] N. Javeed, M. R. Brown, K. Rakshit et al., *Pro-inflammatory cytokines disrupt β-cell circadian clocks in diabetes*, Article ID 7052110, bioRxiv, 2019.

[52] S. Yoo, J. Bae, H. Chin, and G. Koh, “2122-P: system x(c)- is a key molecule in oxidative stress-induced β-cell damage,” *Diabetes*, vol. 68, Supplement 1, 2019.

[53] S. W. Schaffer, C. J. Jong, and M. Mozaffari, “Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited,” *Vascular Pharmacology*, vol. 57, no. 5-6, pp. 139–149, 2012.

[54] E. Daveri, E. Cremonini, A. Mastaloudis et al., “Cyanidin and delphinidin modulate inflammation and altered redox signaling improving insulin resistance in high fat-fed mice,” *Redox Biology*, vol. 18, pp. 16–24, 2018.

[55] M. K. Sagoo and L. Gnudi, “Diabetic nephropathy: is there a role for oxidative stress?”, *Free Radical Biology and Medicine*, vol. 116, pp. 50–63, 2018.

[56] A. Sharma, M. Tate, G. Mathew, J. E. Vine, R. H. Ritchie, and J. B. de Haan, “Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications,” *Frontiers in Physiology*, vol. 9, p. 114, 2018.

[57] K. Karthikesan, L. Pari, and V. P. Menon, “Protective effect of tetrahydrocurcumin and chlorogenic acid against streptozotocin-nicotinamide generated oxidative stress induced diabetes,” *Journal of Functional Foods*, vol. 2, no. 2, pp. 134–142, 2010.

[58] L. Pari, K. Karthikesan, and V. P. Menon, “Comparative and combined effect of chlorogenic acid and tetrahydrocurcumin on antioxidant disparities in chemical induced experimental diabetes,” *Molecular and Cellular Biochemistry*, vol. 341, no. 1-2, pp. 109–117, 2010.

[59] K. Umanath and J. B. Lewis, “Update on diabetic nephropathy: core curriculum 2018,” *American Journal of Kidney Diseases*, vol. 71, no. 6, pp. 884–895, 2018.

[60] L. Bao, J. Li, D. Zha et al., “Chlorogenic acid prevents diabetic nephropathy by inhibiting oxidative stress and inflammation through modulation of the Nrf2/HO-1 and NF-kB pathways,” *International Immunopharmacology*, vol. 54, pp. 245–253, 2018.

[61] H. Ye, Z. Li, Y. Zheng, Y. Chen, Z.-H. Zhou, and J. Jin, “The attenuation of chlorogenic acid on oxidative stress for renal injury in streptozotocin-induced diabetic nephropathy rats,” *Archives of Pharmacal Research*, vol. 39, no. 7, pp. 989–997, 2016.

[62] J. L. Leasher, R. R. Bourne, S. R. Flaxman et al., “Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010,” *Diabetes Care*, vol. 39, no. 9, pp. 1643–1649, 2016.

[63] L. Zhou, T. Zhang, B. Lu et al., “Lonicerae Japonicae Flos attenuates diabetic retinopathy by inhibiting retinal angiogenesis,” *Journal of Ethnopharmacology*, vol. 189, pp. 117–125, 2016.

[64] X. Mei, L. Zhou, T. Zhang, B. Lu, Y. Sheng, and L. Ji, “Chlorogenic acid attenuates diabetic retinopathy by reducing VEGF expression and inhibiting VEGF-mediated retinal neoangiogenesis,” *Vascular Pharmacology*, vol. 101, pp. 29–37, 2018.

[65] J. Y. Shin, J. Sohn, and K. H. Park, “Chlorogenic acid decreases retinal vascular hyperpermeability in diabetic rat model,” *Journal of Korean Medical Science*, vol. 28, no. 4, p. 608, 2013.

[66] B. Watterworth and T. B. Wright, “Diabetic peripheral neuropathy,” in *Pain*, A. Abd-Elsayed, Ed., pp. 911–913, Springer, Cham, 2019.

[67] B. N. Hong, Y. H. Nam, S. H. Woo, and T. H. Kang, “Chlorogenic acid rescues sensorineural auditory function in a diabetic animal model,” *Neuroscience Letters*, vol. 640, pp. 64–69, 2017.

[68] D. Bagdas, H. Y. Ozboluk, N. Cinkilic, and M. S. Gurun, “Antinociceptive effect of chlorogenic acid in rats with painful diabetic neuropathy,” *Journal of Medicinal Food*, vol. 17, no. 6, pp. 730–732, 2014.